Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with the Combination of Venetoclax plus Azacitidine(VEN+AZA).
A lower OS and EFS were associated with a higher treatment discontinuation rate, lower number of treatment cycles, and lower CRc achievement rate than those observed in the VIALE-A trial. We considered that treatment continuation was important to improve the prognosis. We also concluded that it is important to select candidates suitable for VEN+AZA treatment and to modify the administration schedule.
Authors
- Hiroaki Kanda (ORCID: https://orcid.org/0000-0002-4602-5938)
- Daisuke Takei (ORCID: https://orcid.org/0000-0002-4957-6030)
- Masaaki Noguchi (ORCID: https://orcid.org/0000-0001-9458-2707)
- Yu Nishimura
- Tomoya Abe
- Hiroki Tsutsumi (ORCID: https://orcid.org/0000-0001-8852-9328)
- Nobuo Maseki (ORCID: https://orcid.org/0000-0002-3088-6311)
- M Kawamura (ORCID: https://orcid.org/0000-0002-6138-1690)
- Yoshie Iizaki
- Hirofumi Kobayashi (ORCID: https://orcid.org/0009-0000-3588-3788)
- Kazuhiko Kobayashi
- Masahisa Kudo
- Yasunobu Sekiguchi
Institutions
- Saitama Cancer Center (JP)
Publication Details
- Journal
- PubMed
- Published
- 2024-11-01
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00